Results 121 to 130 of about 20,319 (246)

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7416-7429, August 2026.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7471-7482, August 2026.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale, K. G. Young, P. Cardoso, L. M. Güdemann, T. T. Jansz, A. P. McGovern, A. G. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. M. Shields, J. M. Dennis   +11 more
wiley   +1 more source

Continuous glucose monitoring-based evaluation of percentage coefficient of variation (%CV) as a metric of intraday glycemic variability in South India. [PDF]

Sci Rep
Hussain MA, Kumar H A, Lingaiah M.
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang, Bingyu Zhang, Yiwen Lu, Ying Lu, Anastassia Amaro, Yuan Lu, David A. Wolk, Yong Chen   +7 more
wiley   +1 more source

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Sulfonylurea [PDF]

, 2020
openaire   +1 more source

Understanding Diabetes Distress: A Study of Contributing Factors Among Adults With Type 2 Diabetes in Rural East Godavari, Andhra Pradesh. [PDF]

Cureus
Meka RJ, Sundaram M S, Rani K S G, Mani V, Natrajan M.   +4 more
europepmc   +1 more source